|
Drug
|
IC50(mg.L-1, ± s)
|
RI
|
|---|
| |
Bel-7402
|
Bel-7402/ADMS
|
Bel-7402/ADML
|
Bel-7402/ADMV
|
RIS
|
RIL
|
RIV
|
|---|
|
ADM
|
2.09 ± 0.13
|
26.69 ± 0.46
|
26.92 ± 0.38
|
46.93 ± 0.82
|
12.77
|
12.88
|
22.45
|
|
CDDP
|
0.98 ± 0.11
|
12.92 ± 3.45
|
13.46 ± 3.00
|
25.18 ± 3.57
|
13.18
|
13.73
|
25.69
|
|
MMC
|
0.54 ± 0.05
|
0.57 ± 0.08
|
0.60 ± 0.08
|
0.62 ± 0.04
|
1.06
|
1.11
|
1.15
|
|
MTX
|
0.15 ± 0.05
|
0.17 ± 0.05
|
0.20 ± 0.06
|
0.21 ± 0.05
|
1.13
|
1.33
|
1.4
|
|
5-FU
|
119.65 ± 6.46
|
120.78 ± 4.84
|
121.60 ± 6.15
|
123.66 ± 5.00
|
1.01
|
1.02
|
1.03
|
- Note: By least significant difference (LSD) paired-comparison in both ADM and CDDP groups, except Bel-7402/ADML vs. Bel-7402/ADMS (P > 0.05), there is no statistical significance. In other groups of resistant cells, there is a significant difference by paired-comparison. In addition, in MMC, MTX and 5-FU groups, there is no statistical significance by paired-comparison (P > 0.05).
